IP Verse

Amgen Research Munich competitive analysis

Loading summary...

Latest patents of Amgen Research Munich opposed by its competitors

Explore Amgen Research Munich's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3819007	Jul 10, 2024	Dosing Regimen For Anti-Bcma Agents	3
EP2637670	Mar 13, 2024	Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains	2
EP4058148	Mar 13, 2024	Dosing Regimen For Anti-Bcma Agents	3
EP3531133	Aug 23, 2023	Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients	1
EP3411402	Dec 22, 2021	Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs	1
EP3228315	Nov 25, 2020	Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains	2
EP3412687	Mar 18, 2020	Methods For Treating Dlbcl	1
EP2780375	Sep 11, 2019	Binding Molecules For Bcma And Cd3	8
EP2780374	Aug 21, 2019	Binding Molecules For Bcma And Cd3	7
EP3149480	Dec 26, 2018	Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients	1

Latest publications and patents of Amgen Research Munich New

Explore the latest publications and patents granted to Amgen Research Munich, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Amgen Research Munich
EP3819007	Jul 10, 2024	Dosing Regimen For Anti-Bcma Agents	Granted And Under Opposition
EP4058148	Mar 13, 2024	Dosing Regimen For Anti-Bcma Agents	Granted And Under Opposition
EP2637670	Mar 13, 2024	Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains	Patent Maintained As Amended
EP3531133	Aug 23, 2023	Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients	Revoked
EP3411402	Dec 22, 2021	Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs	Granted And Under Opposition
EP3228315	Nov 25, 2020	Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains	Granted And Under Opposition
EP3412687	Mar 18, 2020	Methods For Treating Dlbcl	Revoked
EP2780375	Sep 11, 2019	Binding Molecules For Bcma And Cd3	Revoked
EP2780374	Aug 21, 2019	Binding Molecules For Bcma And Cd3	Revoked
EP3149480	Dec 26, 2018	Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients	Revoked

Latest PTAB cases involving Amgen Research Munich

Discover the latest PTAB cases involving Amgen Research Munich, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Amgen Research Munich with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
AMGEN RESEARCH MUNICH	-	30	-	-
ABBVIE	10	9	-	1
JAMES POOLE	153	-	-	-
REGENERON PHARMACEUTICALS	38	94	9	31